EBITDA surged 151% to ₹65.5 crore from ₹26 crore a year ago, with margins expanding to 10.9% from 5%. Net profit doubled to ₹50 crore.
Like-for-like revenue growth came in at 21.3%, aided by the Flipkart settlement, while underlying volume growth was robust at 30.2%.Mamaearth reported double-digit growth, and younger brands grew over 25%. The Derma Co also delivered double-digit EBITDA growth.
Distribution expanded meaningfully, with direct outlet coverage crossing 1 lakh outlets and total distribution rising over 25% YoY to 2.7 lakh outlets.
Brokerage reactionsHSBC retains a ‘Reduce’ rating with a price target of ₹260. It said Q3 results were robust, with a 30% EBITDA beat and Mamaearth posting growth in the teens, albeit on a low base.
HSBC raised its EBITDA margin estimates, leading to a 7-18% increase in FY26-28 EPS forecasts, but cautioned that while margin improvement is impressive, consistent growth delivery remains key.
Jefferies remains positive with a ‘Buy’ rating and a price target of ₹500. It said that Mamaearth delivered double-digit growth, while younger brands grew nearly twice as fast, alongside margin expansion.
Management commentary was constructive on both growth and profitability.
Jefferies said that although Honasa’s journey has been bumpy, the company is steadily regaining momentum, which could help rebuild investor confidence. It has sharply raised its earnings estimates following the quarter.
Despite the rally, the stock remains below its IPO price of ₹324.

